recent discoveries and clinical applications of deoxyribonucleic acid (dna) methylation inhibitors in the diagnosis, classification, and treatment of meningiomas

Recent advancements in molecular biology and genomics have revolutionized our understanding of meningiomas, leading to novel diagnostic and treatment strategies. meningiomas are common central nervous system tumors and their management has traditionally relied on histopathological classification. however, the integration of dna methylation analysis has provided new understanding into the molecular activities of these tumors, providing potential biomarkers for personalized medicine. this review involved a comprehensive search of electronic databases (e.g., pubmed, web of science, and scopus) was conducted to identify relevant studies based on keywords related to dna methylation inhibitors, meningioma, diagnosis, classification, and treatment. this study was aimed at assessing the recent discoveries regarding dna methylation inhibitors and their potential clinical applications in diagnosing, classifying, and treating meningiomas. dna methylation inhibitors are applied in modulating gene expression patterns in meningiomas and nucleoside analogs demonstrated potential in inhibiting meningioma cell growth by inducing apoptosis through dna hypomethylation. these inhibitors, when used in combination with conventional treatments, could enhance treatment efficacy, overcome drug resistance, and reduce tumor recurrence, as they can be specifically used to target specific molecular subtypes of meningiomas.